標題: Titlebook: Applications of Biotechnology in Oncology; Kewal K. Jain Book 2014 Springer Science+Business Media New York 2014 Anticancer agents.Cancer [打印本頁] 作者: incoherent 時間: 2025-3-21 16:47
書目名稱Applications of Biotechnology in Oncology影響因子(影響力)
書目名稱Applications of Biotechnology in Oncology影響因子(影響力)學科排名
書目名稱Applications of Biotechnology in Oncology網(wǎng)絡公開度
書目名稱Applications of Biotechnology in Oncology網(wǎng)絡公開度學科排名
書目名稱Applications of Biotechnology in Oncology被引頻次
書目名稱Applications of Biotechnology in Oncology被引頻次學科排名
書目名稱Applications of Biotechnology in Oncology年度引用
書目名稱Applications of Biotechnology in Oncology年度引用學科排名
書目名稱Applications of Biotechnology in Oncology讀者反饋
書目名稱Applications of Biotechnology in Oncology讀者反饋學科排名
作者: 檔案 時間: 2025-3-21 20:17 作者: 乞討 時間: 2025-3-22 03:30
Biomarkers of Cancer,teration of a cell on DNA, RNA, metabolite, or protein level can be referred to as a molecular biomarker. In the era of molecular biology, biomarkers usually mean molecular biomarkers and can be divided into three broad categories (Jain 2010):作者: jealousy 時間: 2025-3-22 06:08
Book 2014terature on this topic and numerous tables and figures, .Applications of Biotechnology in Oncology. serves as an ideal reference for oncologists, scientists involved in research on cancer biology, and physicians in various specialties who deal with cancer.作者: DNR215 時間: 2025-3-22 10:00
Firm Performance and Employee Relations, patients’ health. Oncogenomics has assumed importance as a guide to management and development of personalized cancer therapies. Gene expression profiling of tumors is also used for developing targeted anticancer therapies.作者: degradation 時間: 2025-3-22 15:14 作者: 剝削 時間: 2025-3-22 17:37
https://doi.org/10.1007/978-1-349-01784-3 a static snapshot of the various ways in which the cell might use its proteins, whereas the life of the cell is a dynamic process. With this background, DNA/RNA (ribonucleic acid) sequences, per se, are not enough for the clear identification of a therapeutic target because proteins and not DNA/RNA are the basis of mode of action of drugs.作者: intertwine 時間: 2025-3-22 21:19 作者: commensurate 時間: 2025-3-23 03:35
Sequencing in Cancer,hnologies means determination of variations of DNA sequence in an organism where the nominal sequence is already known. It is often performed using PCR to amplify the region of interest (preexisting DNA sequence is required to design the PCR primers). Resequencing is more relevant for translation into diagnostics and clinical applications.作者: Cupping 時間: 2025-3-23 06:11
Oncoproteomics, a static snapshot of the various ways in which the cell might use its proteins, whereas the life of the cell is a dynamic process. With this background, DNA/RNA (ribonucleic acid) sequences, per se, are not enough for the clear identification of a therapeutic target because proteins and not DNA/RNA are the basis of mode of action of drugs.作者: 開始發(fā)作 時間: 2025-3-23 10:13
https://doi.org/10.1007/978-3-319-97559-7cancer action. Important methods of immunotherapy for cancer are cytokines, monoclonal antibodies (MAbs), vaccines, and immunogene therapy. Following an introduction to cytokines, cancer vaccines will be the focus of this chapter. MAbs will be dealt with in Chap. 8 and immunogene therapy in Chap. 11.作者: VEIL 時間: 2025-3-23 14:17
Book 2014arch, particularly to the molecular diagnosis of cancer and drug delivery in cancer for personalized management of patients. Basics of various “omics” technologies and their application in oncology are described as oncogenomics and oncoproteomics.?This detailed volume also explores molecular diagnos作者: 甜得發(fā)膩 時間: 2025-3-23 20:55 作者: pulmonary-edema 時間: 2025-3-23 23:12 作者: Cholesterol 時間: 2025-3-24 03:34 作者: AVID 時間: 2025-3-24 07:18
https://doi.org/10.1007/978-981-13-2820-6ies, including siRNAs, repeat-associated siRNAs (rasiRNAs), and microRNAs (miRNAs); the last type is described in Chap. 13. Basics of RNAi and details of RNAi-based therapeutics are described in detail in a special report on this topic (Jain 2013).作者: 生銹 時間: 2025-3-24 12:08 作者: LEERY 時間: 2025-3-24 14:56 作者: glacial 時間: 2025-3-24 22:13 作者: cognizant 時間: 2025-3-25 03:05
Role of RNAi in Cancer,ies, including siRNAs, repeat-associated siRNAs (rasiRNAs), and microRNAs (miRNAs); the last type is described in Chap. 13. Basics of RNAi and details of RNAi-based therapeutics are described in detail in a special report on this topic (Jain 2013).作者: Axon895 時間: 2025-3-25 06:06
Personalized Cancer Therapy,on various omics such as genomics, proteomics, and metabolomics and biomarkers. The aim of the personalized medicine is to match the right drug to the right patient. The broad scope of personalized medicine includes predisposition testing, determination of prognosis, combination of diagnostics with therapeutics, and monitoring of therapy.作者: Intellectual 時間: 2025-3-25 08:27
https://doi.org/10.1007/978-3-322-81849-2apy. The cells may be introduced by various routes into the body and selectively implanted at the site of action. More recently, cell therapies have expanded to replace some conventional procedures. Bone marrow (BM) transplants are being replaced by peripheral blood stem cell (PBSC) transplants. Mos作者: organism 時間: 2025-3-25 12:51 作者: ASSAY 時間: 2025-3-25 18:39 作者: harbinger 時間: 2025-3-25 20:23 作者: 包庇 時間: 2025-3-26 04:07
Oncology. serves as an ideal reference for oncologists, scientists involved in research on cancer biology, and physicians in various specialties who deal with cancer.978-1-4939-4890-1978-1-4614-9245-0作者: Odyssey 時間: 2025-3-26 06:05 作者: enumaerate 時間: 2025-3-26 10:07 作者: 集聚成團 時間: 2025-3-26 14:33 作者: 疏遠天際 時間: 2025-3-26 19:52
Role of Biotechnology in Drug Delivery for Cancer,herapies, require new concepts of drug delivery in cancer. New biotechnologies have contributed considerably to drug delivery in cancer and some of these have been considered in other chapters: monoclonal antibodies (MAbs) (Chap. 8), nanobiotechnology/nanooncology (Chap. 9), cell therapy (Chap. 10),作者: Flatus 時間: 2025-3-26 22:36 作者: 指令 時間: 2025-3-27 03:03
Sequencing in Cancer, determining the exact order of the three billion nucleotide bases—adenine, guanine, cytosine, and thymine—that make up the DNA of the 23 pairs of human chromosomes. In de novo sequencing, short DNA fragments purified from individual bacterial colonies are individually sequenced and assembled electr作者: 共和國 時間: 2025-3-27 08:02 作者: chalice 時間: 2025-3-27 12:17
Biomarkers of Cancer, pharmacological response to a therapeutic intervention. In case of cancer, biomarkers are referred to as cancer biomarkers. Any specific molecular alteration of a cell on DNA, RNA, metabolite, or protein level can be referred to as a molecular biomarker. In the era of molecular biology, biomarkers 作者: carbohydrate 時間: 2025-3-27 17:32 作者: Intractable 時間: 2025-3-27 19:06 作者: Facet-Joints 時間: 2025-3-27 23:33
Monoclonal Antibodies and Cancer,ll surfaces, compromising their function. MAbs may also be used to recruit the cellular arm of the immune system, planting a homing beacon on the transformed cell. MAbs, although produced in the laboratory, mimic the antibodies naturally produced by the body as part of immune system’s response to di作者: 公共汽車 時間: 2025-3-28 02:12
Nanooncology,anometer-length scale, i.e., at the level of atoms, molecules, and supramolecular structures. Nanotechnology, as defined by the National Nanotechnology Initiative (.), is the understanding and control of matter at dimensions of roughly 1–100 nm, where unique phenomena enable novel applications. Enco作者: Barrister 時間: 2025-3-28 09:39
Cell Therapy of Cancer, treated or altered outside the body (ex vivo). The scope of cell therapy can be broadened to include methods, pharmacological as well as non-pharmacological, to modify the function of intrinsic cells of the body in vivo for therapeutic purposes. The aim of cell therapy is to replace, repair, or enh作者: 貿(mào)易 時間: 2025-3-28 12:07
Gene Therapy of Cancer,tering a particular disease state (Jain 1998). It has three components: (1) identification of the gene that is mutated in a disease and obtaining a healthy copy of that gene, (2) carrier or delivery vehicle called vectors to deliver the healthy gene to a patient’s cells, and (3) additional DNA eleme作者: ANNUL 時間: 2025-3-28 15:33
Role of RNAi in Cancer,f the technologies for suppression of gene function of which the best known involves the use of antisense oligonucleotides. RNAi involves the use of a double-stranded RNA (dsRNA). Once in the cell, the dsRNAs are processed into short, 21–23 nucleotide dsRNAs termed small interfering RNAs (siRNAs) th作者: sacrum 時間: 2025-3-28 20:00
Role of MicroRNAs in Cancer,diverse multicellular organisms. miRNAs are 21–25 nucleotide transcripts that repress gene function through interactions with target mRNAs. More detailed information is contained in a special report on microRNAs (Jain 2014).作者: TAG 時間: 2025-3-29 02:59
Biotechnology in Drug Discovery and Development for Cancer,e screened in a given assay. Even though many thousands of distinct chemical structures exist, it is not unusual for screening utilizing this approach to be terminated at the end of several years with no lead compounds identified, having examined only a small fraction of available compounds. This li作者: minaret 時間: 2025-3-29 03:31 作者: HAUNT 時間: 2025-3-29 09:24 作者: Phenothiazines 時間: 2025-3-29 13:26
Kewal K. JainContains excerpts from Prof. Kewal K. Jain‘s key writings on biotechnology and cancer.Features around a thousand selected references from recent literature on the topic as well as 53 tables and 10 fig作者: APRON 時間: 2025-3-29 18:30
http://image.papertrans.cn/a/image/159315.jpg作者: sleep-spindles 時間: 2025-3-29 21:59
https://doi.org/10.1007/978-1-4614-9245-0Anticancer agents; Cancer drug delivery; Cell and gene therapy; Molecular diagnostics; Nanobiotechnology作者: SPECT 時間: 2025-3-30 00:38
978-1-4939-4890-1Springer Science+Business Media New York 2014作者: Neutral-Spine 時間: 2025-3-30 07:29 作者: 粘土 時間: 2025-3-30 10:23 作者: 丑惡 時間: 2025-3-30 13:01
https://doi.org/10.1007/978-3-319-97559-7omics (Chap. 2), sequencing (Chap. 3), oncoproteomics (Chap. 4), and biomarkers (Chap. 5) are relevant to molecular diagnosis of cancer. Basic molecular diagnostic technologies are described in detail in a special report on this topic (Jain 2013). Some of the technologies used for diagnosis of cancer are described in this chapter.作者: 著名 時間: 2025-3-30 16:35
Emma Parry,Graeme Martin,Joe Dromeydiverse multicellular organisms. miRNAs are 21–25 nucleotide transcripts that repress gene function through interactions with target mRNAs. More detailed information is contained in a special report on microRNAs (Jain 2014).作者: Aviary 時間: 2025-3-30 22:16
Firm Performance and Employee Relations,enomic research has provided a stratification of cancer types. Genomics as applied to cancer or oncogenomics provides an unprecedented opportunity for the discovery of potential new targets. Through the establishment of a suite of research programs, the National Cancer Institute (NCI) of the USA is 作者: 按時間順序 時間: 2025-3-31 02:10
https://doi.org/10.1057/9780230592001 determining the exact order of the three billion nucleotide bases—adenine, guanine, cytosine, and thymine—that make up the DNA of the 23 pairs of human chromosomes. In de novo sequencing, short DNA fragments purified from individual bacterial colonies are individually sequenced and assembled electr作者: 牢騷 時間: 2025-3-31 07:11
https://doi.org/10.1007/978-1-349-01784-3rs to all proteins produced by a species, much as the genome is the entire set of genes. Unlike the genome, the proteome varies with time and is defined as “the proteins present in one sample (tissue, organism, cell culture) at a certain point in time.” Proteomics parallels the related field of geno作者: irritation 時間: 2025-3-31 12:01
Employee Relations within the Factory pharmacological response to a therapeutic intervention. In case of cancer, biomarkers are referred to as cancer biomarkers. Any specific molecular alteration of a cell on DNA, RNA, metabolite, or protein level can be referred to as a molecular biomarker. In the era of molecular biology, biomarkers 作者: Ejaculate 時間: 2025-3-31 15:05 作者: CLEAR 時間: 2025-3-31 18:09 作者: 百科全書 時間: 2025-3-31 23:35
